NIKKEI 225
27,581.66-388.56(-1.39%)HANG SENG
25,473.88+387.45(+1.54%)CRUDE OIL
72.37+0.72(+1.00%)GOLD FUTURES
1,806.00+6.20(+0.34%)DOW
34,930.93-127.59(-0.36%)BTC-GBP
28,770.14+1,032.60(+3.72%)
COMPASS Pathways plc (CMPS)
After hours: 04:41PM EDT
| Previous close | 36.97 |
| Open | 36.65 |
| Bid | 35.65 x 1000 |
| Ask | 36.03 x 800 |
| Day's range | 35.63 - 37.20 |
| 52-week range | 22.51 - 61.69 |
| Volume | 469,860 |
| Avg. volume | 492,168 |
| Market cap | 1.468B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.70 |
| Earnings date | 12 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 68.50 |
- Globe Newswire
Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
London, UK – 21 July 2021 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced that it has appointed Danielle Schlosser PhD as Senior Vice-President, Clinical Innovation. Dr Schlosser will lead COMPASS’s Therapy Research and Training team, bringing her clinical experience in behavioural health and experience in digital health innovation. Danielle Schlosser joins COMPASS from
- Motley Fool
Is It Too Early to Invest in Psychedelic Stocks?
Legislation is starting to open up the industry but investors who are hoping to cash in on its growth opportunities could be waiting a very long time.
- Investor's Business Daily Video
Psychedelic-Drug Developers Bring Hallucinogens To The World Of Therapeutics
More psychedelic drug companies over the past year have tried to reach investors via U.S. and Canadian exchanges.
